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CORONARY HEART DISEASE (CHD) is
a major cause of morbidity and mortal-
ity in Australia.1 Secondary and pri-
mary prevention are acknowledged as
appropriate strategies for reducing mor-
bidity and mortality, with guidelines
focusing on the major risk factors of
age, smoking, high blood pressure, cho-
lesterol levels, family history and diabe-
tes.2 Absolute rather than relative risk is
now used to determine who might ben-
efit most from treatment.3 However,
application of risk-factor tables by gen-
eral practitioners is problematic,4,5 and
it is thought that many individuals with,
or at risk of, CHD are currently not
receiving adequate treatment.6,7 Man-
agement of hyperlipidaemia is of partic-
ular concern, because of the high cost of
statins to the Pharmaceutical Benefits
Scheme (PBS) — $806 million from
December 2002 to November 2003.8
It is well known that morbidity and
mortality from heart disease is greatest
in lower socioeconomic groups.1 Fur-
thermore, it is thought that women, at
least for secondary prevention of CHD,
are less likely than men to receive treat-
ment.9 It is not known if there is differ-
ential prescribing of statins in Australia.
If there is, this might be evidence of the
inverse care law,10 and might have
implications for the PBS budget.
As part of a cardiovascular risk assess-
ment project in general practice, we
sought to identify if statin prescribing
varies by socioeconomic status in Aus-
tralia and if there are any differences in
rates of prescribing for men and
women.
METHODS
The Australian Department of Health
and Ageing provided data about statin
prescriptions subsidised through the
PBS and Repatriation Pharmaceutical
Benefits Scheme. Because the cheapest
statin is $28.99, which is above the
patient copayment fee ($22.40 for Aus-
tralians in general and $3.60 for con-
cession card holders at February
2002), we expect information on most
statins prescribed in Australia to be
available.
Data provided by the Department of
Health and Ageing included item num-
bers for atorvastatin, fluvastatin, prava-
statin and simvastatin. Data by age,
postcode and sex were only available for
May to December 2002. The number of
scripts and associated costs in this 8-
month period were divided by eight to
give average monthly estimates.
The Socio-economic Indexes for
Areas (SEIFA) was used to characterise
the socioeconomic quintile of each post-
code in Australia, using the Index of
Relative Socio-economic Disadvantage
(IRSD).11 The index is based on such
factors as percentage of dwellings being
rented, percentage of persons unem-
ployed, in relatively unskilled occupa-
tions, lacking fluency in English,
Aboriginal or Torres Strait Islanders,
and relatively low educational attain-
ment. The scores are based on ques-
tions asked in the 1996 census, and are
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Objective:  To assess if there are any differences in statin prescribing across Australia 
by socioeconomic status or sex and to relate prescribing rates to coronary heart 
disease (CHD) mortality rates.
Design:  Cross-sectional study using data on statin prescribing by age, sex and 
patient postcode for the period May to December 2002.
Setting and participants:  The Australian population, stratified by sex and quintile 
of Index of Relative Socio-Economic Disadvantage (IRSD).
Main outcome measures:  Age-standardised rates of statin scripts per 1000 
population per month for each sex and IRSD quintile.
Results:  9.1 million prescriptions for statins were supplied between May and 
December 2002, for a total cost of $570 million. The age-standardised rates for statin 
prescribing in women varied from 56.9 (95% CI, 56.6–57.2) scripts per 1000 
population per month in the most disadvantaged socioeconomic quintile through 53.4 
(95% CI, 53.0–53.7), 50.3 (95% CI, 50.0–50.6), 48.4 (95% CI, 48.1–48.7) to 46.3 
(95% CI, 46.0–46.6) in the least disadvantaged quintile. For men the figures were 
52.6 (95% CI, 52.3–52.9), 50.9 (95% CI, 50.6–51.2), 48.8 (95% CI, 48.6–49.1), 
47.7 (95% CI, 47.4–47.9), and 51.9 (95% CI, 51.6–52.2). There was a significant linear 
association between statin prescribing and CHD mortality by quintile of socioeconomic 
disadvantage in women (weighted least squares slope, 0.380; 95% CI, 0.366 to 0.395; 
P < 0.0001), but not in men (slope, −0.002; 95% CI, −0.010 to 0.006; P = 0.65).
Conclusions:  Our results suggest that in men there is either overprescribing of 
statins in the highest socioeconomic quintile or underprescribing in the lowest. 
Furthermore, contrary to expectation, women — relative to men — are prescribed 
statins at higher rates at lower levels of risk (using CHD deaths as a proxy 
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provided at the postcode level. Data for
1996 were the most recent available at
the time of writing.
Each statin script was assigned to a
socioeconomic quintile based on post-
code. Direct age standardisation was
used to estimate the rate of statin scripts
per 1000 population in each IRSD
quintile for each sex separately, as the
burden of cardiovascular disease varies
substantially by sex. The 1991 Austral-
ian population by age group (< 25, 25–
34, 35–44, 45–54, 55–64, 65–74, and
 75 years) and sex was used as the
standard population.12
We used weighted linear regression
models for each sex to examine the
relation between statin prescribing rates
for each IRSD quintile and the corre-
sponding mortality rates
from CHD. Mortality rates
were based on deaths in
1997, standardised to the
1991 Australian population
(as these were the only data
available by socioeconomic
quintile).13 The regression
weights were the inverses of
the variances of the pre-
scribing rates in each quin-
tile.
All analyses were per-
formed using SAS.14
RESULTS
There were 9.1 million pre-
scriptions filled for statins
between May and Decem-
ber 2002. The government
subsidy for these was $506
million, and the patient contribution
$64 million (total cost, $570 million).
Most of the prescriptions (94.6%) were
written by GPs rather than Other Medi-
cal Providers. Because of missing data,
2.7% of scripts were removed from the
analysis.
Age-specific rates (scripts per 1000
population per month) showed substan-
tial variation: 25–34 years, 2.0; 35–44
years, 13.1; 45–54 years, 55.4; 55–64
years, 156.3; 65–74 years, 271.7; and
 75 years, 230.4. For all ages, the rate
was 56.8 scripts per 1000 population
per month. Age-standardised rates by
quintile of socioeconomic disadvantage
for each sex are shown in Box 1. Exami-
nation of the confidence intervals indi-
cates that each quintile has different
rates of statin prescribing.
Box 2 shows that, although deaths
from CHD (used here as a proxy for
cardiovascular risk) are lowest in the
least disadvantaged in both sexes, statin
prescribing in men in this group appears
to be disproportionately high compared
with other socioeconomic quintiles. The
regression analysis for men confirmed
no significant linear relation between
statin prescribing and CHD mortality
(slope, 0.002; 95% CI, 0.010 to
0.006; P= 0.65). In women, there was a
significant linear relation (slope, 0.380;
95% CI, 0.366 to 0.395; P< 0.0001).
DISCUSSION
Our study indicates that men living in
the least disadvantaged socioeconomic
areas of Australia have higher rates of
statin prescribing relative to their cardio-
vascular risk compared with other men.
We cannot be sure whether this differ-
ence is due to underprescribing in the
lowest socioeconomic quintiles or over-
prescribing in the highest (with potential
costs or savings for the PBS budget), but
it appears to be evidence of the inverse
care law — that medical care varies
inversely with need.10
Although our study cannot provide a
causal explanation for these findings, we
speculate that there may be a range of
drivers for statin prescribing. First,
patient expectation might




their current and future
healthcare and more likely
to have adopted messages
about men’s health. Those
with health insurance (more
likely to be the least disad-
vantaged)15 are probably
more likely to be referred,16
be investigated and receive
treatment for identified risk
factors. Patients in wealthy
areas are more likely to have
long consultations with their
GP.17 This extra time could
well be spent in preventive
activities that would not be
available to patients access-
ing care from GPs predominantly serv-
icing lower socioeconomic areas. Do
GPs, who are still predominantly male,
middle-aged and middle class,18 iden-
tify more strongly with their peers in a
way that influences their preventive
message and prescribing behaviour?
Our study also shows high rates of
statin prescribing for women compared
with men. Women in the lowest socio-
economic group receive more statin
scripts than any other group. Impor-
tantly, despite being at much lower risk
of death from CHD, women in this
group receive more statins than men in
similar economic circumstances. This is
contrary to evidence from the United
2: Mortality* from coronary heart disease,† and 
prescribing rates for statins, by socioeconomic group‡
* Mortality rate per 100000 population, using 1991 IRSD and standard population 
and 1997 deaths. † Scripts per 1000 population per month, from 2002 prescribing 
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Kingdom which suggests that women
with established CHD are less likely to
be prescribed lipid-lowering medication
than men.9 Again, we can only speculate
as to the reasons for these differences.
We know that attendance at GPs is
greatest among women, including
attendance for cardiovascular prob-
lems,19 so it is possible that the oppor-
tunity to discuss primary and secondary
prevention with a GP is important. We
know that women are more likely to
self-report diseases of the circulatory
system (including hypertensive disease,
CHD and varicose veins) and diabetes
than men, at least in the lowest socio-
economic group.15 This might account
for some of the difference, although
women’s rates of smoking are less than
rates in men and could balance any
increased risk due to diabetes and
hypertension.
New lipid management guidelines
have been published,20 and it has been
suggested that previous guidelines in
Australia were poor discriminators of
absolute CHD risk for primary preven-
tion.21 GPs using inappropriate guide-
lines might explain some of the
observed differences, but this would
require differential application to men
and women across the socioeconomic
spectrum. Finally, we do not know if the
observed differences are due to the use
of statins for primary or secondary pre-
vention.
There are several potential limita-
tions in this study. We described the
collection of statins as “prescribing”
when, strictly, it is “dispensing”, so we
have not accounted for scripts that
were prescribed but not dispensed, or
scripts that were dispensed but not
taken. Poor compliance with lipid-low-
ering drugs has been identified previ-
ously in the Australian population;22
however, no sex differences in compli-
ance were found, so our results are
unlikely to be explained purely by dif-
ferential levels of compliance. Sec-
ondly, we cannot be sure that just
because a person lives in an area of
socioeconomic advantage or disadvan-
tage that he or she shares the same
socioeconomic status as his or her
neighbours. However, the SEIFA index
is well accepted and any such misclassi-
fication would diminish rather than
enhance our findings. Finally, we have
used several sources of data ranging
from 1990 to 2002. The age structure
of the Australian population has
changed in that time, and cardiovascu-
lar morbidity and mortality have fallen,
although the evidence suggests any
decline has been uniform across socio-
economic groups.23 Again, all these
limitations affect the size of any differ-
ence, not the direction.
Our results suggest that, for men,
there is either overprescribing of statins
in the least disadvantaged group or
underprescribing in the most disadvan-
taged, with a gradient across quintiles of
socioeconomic disadvantage. Further-
more, contrary to expectation, women
are prescribed statins at higher rates at
lower levels of risk (using CHD deaths
as a proxy measure of risk) than men.
Although the differences we have identi-
fied may seem small, even small differ-
ences in prescribing rates can make
substantial differences in costs, morbid-
ity and mortality. Further research
should be undertaken to explore the
reasons behind these differences and
initiatives undertaken to reduce health-
care inequalities.
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